| Title | Author(s) | Year | View Count |  | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Baselga, J; Bradbury, I; Eidtmann, H; Di Cosimo, S; de Azambuja, E; Aura, C; Gomez, H; Dinh, P; Fauria, K; Van Dooren, V; Aktan, G; Goldhirsch, A; Chang, TW; Horvath, Z; Coccia-Portugal, M; Domont, J; Tseng, LM; Kunz, G; Sohn, JH; Semiglazov, V; Lerzo, G; Palacova, M; Probachai, V; Pusztai, L; Untch, M; Gelber, RD; Piccart-Gebhart, M; NeoALTTO Study Team,; Kwong, A | 2012 | 82 |
| Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B | Ahn, SH; Kweon, YO; Paik, SW; Sohn, JH; Lee, KS; Kim, DJ; Piratvisuth, T; Yuen, MF; Chutaputti, A; Chao, YC; Trylesinski, A; Avila, C | 2012 | 102 |
| A phase IIb study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B | Lai, CL; Ahn, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NW; Kwon, YO; Sohn, JH; Lee, JY; Park, HE; Kim, JA; Han, KH; Yuen, MF | 2011 | 211 |
| Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B | Lai, CL; Ahh, SH; Lee, KS; Um, SH; Cho, M; Yoon, SK; Lee, JW; Park, NH; Kweon, YO; Sohn, JH; Lee, J; Kim, JA; Han, KH; Yuen, MF | 2011 | 61 |
|
